SOMATOTROPIC RESEARCH

Tesamorelin: GHRH Analogue in Growth Hormone Research

Velox Peptides Research Team·Published May 2026·6 min read
CAS Number
218949-48-5
Peptide Class
GHRH analogue
Target
GHRH receptor
HPLC Purity
≥99% (batch-verified)
For in vitro research use only. This summary of the preclinical literature is provided for scientific reference, not medical advice. Tesamorelin is not for human or veterinary consumption.

What is Tesamorelin?

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH), the hypothalamic peptide that signals the pituitary gland to release growth hormone. It is the full 44-amino-acid GHRH sequence with a stabilising chemical modification on the N-terminus that increases its resistance to enzymatic breakdown, giving it a longer functional half-life than native GHRH in research settings.

As a GHRH-receptor agonist, Tesamorelin is studied as a tool for investigating the upstream control of the growth-hormone axis — how the pituitary responds to GHRH-receptor stimulation — rather than as a source of growth hormone itself.

GHRH-receptor signalling vs direct GH

Pulsatile secretion. A key research distinction is that GHRH analogues like Tesamorelin act upstream: they stimulate the pituitary to release the body’s own growth hormone in its natural pulsatile rhythm. This differs mechanistically from administering growth hormone directly, which bypasses the pituitary and produces a non-pulsatile profile. For researchers, this makes Tesamorelin a tool for studying the physiological feedback loops of the GH axis that direct GH administration does not preserve.

Receptor mechanism. Tesamorelin binds the GHRH receptor on pituitary somatotroph cells, a G-protein-coupled receptor whose activation raises intracellular cAMP and triggers GH release. Preclinical models use it to probe somatotroph responsiveness and GH-axis regulation.

Tesamorelin and CJC-1295

Tesamorelin is often studied alongside CJC-1295, another GHRH analogue. Both act on the GHRH receptor, but they differ in structure and half-life characteristics, giving researchers two related but distinct tools for comparative somatotropic studies. Both sit within the somatotropic research category.

Velox Peptides supply information

Velox Peptides supplies Tesamorelin as a lyophilised powder at ≥99% HPLC-verified purity with a batch certificate of analysis available on request. For reconstitution, see the reconstitution calculator. Supplied strictly as a research reagent for in vitro use.

References & further reading

  1. Ferdinandi ES et al. “Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue.” Basic & Clinical Pharmacology & Toxicology, 2007.
  2. Falutz J et al. “Metabolic effects of a growth hormone-releasing factor in patients with HIV.” New England Journal of Medicine, 2007. (Human clinical data — included for mechanistic context only.)

Summaries are paraphrased from the peer-reviewed preclinical literature. For full source citations, email veloxpeps@gmail.com.

Frequently asked questions

What is Tesamorelin?
Tesamorelin is a stabilised synthetic analogue of growth-hormone-releasing hormone (GHRH) that acts on the GHRH receptor. Velox Peptides supplies it for in vitro research use only.
How does Tesamorelin differ from growth hormone?
Tesamorelin acts upstream of growth hormone: it stimulates the pituitary to release the body's own GH in a natural pulsatile rhythm, whereas direct GH administration bypasses the pituitary entirely.
How does Tesamorelin compare to CJC-1295?
Both are GHRH analogues acting on the same receptor, but they differ in structure and half-life, giving researchers two related tools for comparative somatotropic studies.
What purity is Velox Peptides Tesamorelin?
Tesamorelin is HPLC-verified at a minimum of ≥99% purity, with batch documentation available on request.
Is Tesamorelin legal to buy in the UK?
Yes — for in vitro research purposes. It is not supplied for human or veterinary use. Velox Peptides supplies it solely as a research reagent.
Compliance statement. Velox Peptides supplies research reagents for in vitro use by qualified researchers. Every compound is sold strictly as a research reagent. No product is a medicinal product within the meaning of the Human Medicines Regulations 2012. No product has been evaluated by the MHRA or FDA. No product is intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. Any use outside lawful scientific research is outside the scope of sale. See our Research Use Policy and MHRA Statement.

All research summaries on this page are derived from publicly available peer-reviewed literature. Velox Peptides makes no therapeutic claims. For research use only.